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ReviewMicromanaging aerobic respiration and
glycolysis in cancer cellsAyla V. Orang, Janni Petersen, Ross A. McKinnon, Michael Z. Michael*ABSTRACT
Background: Cancer cells possess a common metabolic phenotype, rewiring their metabolic pathways from mitochondrial oxidative phos-
phorylation to aerobic glycolysis and anabolic circuits, to support the energetic and biosynthetic requirements of continuous proliferation and
migration. While, over the past decade, molecular and cellular studies have clearly highlighted the association of oncogenes and tumor sup-
pressors with cancer-associated glycolysis, more recent attention has focused on the role of microRNAs (miRNAs) in mediating this metabolic
shift. Accumulating studies have connected aberrant expression of miRNAs with direct and indirect regulation of aerobic glycolysis and associated
pathways.
Scope of review: This review discusses the underlying mechanisms of metabolic reprogramming in cancer cells and provides arguments that
the earlier paradigm of cancer glycolysis needs to be updated to a broader concept, which involves interconnecting biological pathways that
include miRNA-mediated regulation of metabolism. For these reasons and in light of recent knowledge, we illustrate the relationships between
metabolic pathways in cancer cells. We further summarize our current understanding of the interplay between miRNAs and these metabolic
pathways. This review aims to highlight important metabolism-associated molecular components in the hunt for selective preventive and
therapeutic treatments.
Major conclusions: Metabolism in cancer cells is influenced by driver mutations but is also regulated by posttranscriptional gene silencing.
Understanding the nuanced regulation of gene expression in these cells and distinguishing rapid cellular responses from chronic adaptive
mechanisms provides a basis for rational drug design and novel therapeutic strategies.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In the 1920s, Otto Warburg reported for the first time that while cells
under normal conditions utilize glucose to derive 70% of required ATP
through mitochondrial oxidative phosphorylation (OXPHOS), cancer
cells metabolize glucose by glycolysis even in the presence of
adequate oxygen supply [1,2]. Since then, aerobic glycolysis has been
regarded as a hallmark of cancer that provides bioenergetic, biosyn-
thetic and redox balance advantages for cancer cells [3].
Although Warburg’s seminal studies resulted in a misinterpretation
that irreversible inactivation of mitochondrial respiration is the primary
and sole cause of aerobic glycolysis in cancer cells, later it was re-
ported that impaired respiration is inadequate to explain the metabolic
shift [4]. The study of cancer cell glycolysis continues to surprise,
revealing further associations between a metabolic switch in cancer
cells, mutations in mitochondrial metabolic enzymes and altered
mitochondrial function [5,6]. In addition, discoveries that associate
oncogene and tumor suppressor gene dysfunction with metabolic
reprogramming suggest that both environmental and genetic factors
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the roles of these small non-coding RNAs in fine-tuning gene
expression at different stages of tumourigenesis. Accumulating evi-
dence supports the involvement of miRNAs in modulating cancer cell
metabolism by directly and indirectly regulating genes associated with
aerobic glycolysis [9].
microRNAs (miRNAs) are small non-coding RNAs that canonically play
a major role in post-transcriptional gene repression. Themselves the
products of RNA polymerase II or III dependent transcription, primary
(pri)-miRNA transcripts are 50-7-methylguanosine capped, spliced and
30-polyadenylated and may give rise to one or more mature miRNAs.
Some miRNAs may also derive from processed intronic sequences
[10]. In the nucleus, pri-miRNAs are subjected to cleavage by Drosha
releasing precursor (pre)-miRNA hairpin structures. Pre-miRNAs are
then transported to the cytoplasm where cleavage by Dicer results in a
19e24 nucleotide double-stranded miRNA of which one strand, the
mature miRNA, is transferred to the Argonaute (AGO) component of the
RNA-induced silencing complex (RISC). AGO acts as a RISC effector
protein modulating mRNA stability and translation [11,12].Adelaide, South Australia 5042, Australia
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This review summarizes recent knowledge of the causes and conse-
quences of the Warburg effect, paying particular attention to the
contribution of miRNAs. It also aims to further discuss complex in-
teractions between metabolic pathways and mitochondrial function, as
well as oncogenic and tumor suppressor mutations. Finally, in view of
recent findings, future approaches that can be exploited for therapeutic
benefit are discussed.
2. METABOLIC REPROGRAMMING
Proliferating cells and, indeed, cancer cells require constant cell
division. In order to maintain this, there is an urgent need to
provide a consistent energy source, macromolecular biosynthesis,
and controlled redox status. Therefore, to optimize proliferation,
growth, and survival, cancer cells redirect their metabolic path-
ways and alter the production and consumption of numerous
metabolites [13,14].
To support cancer cell proliferation, glycolysis provides the precursors
for major macromolecules including the carbohydrates, proteins,
lipids, and nucleic acids needed to produce a new cell. Therefore,
aerobic glycolysis imbues cancer cells with ribose, amino acids and
fatty acids [15,16]. The upregulation of glycolysis is mostly due to the
increased expression of enzymes and transporters involved in glucose
uptake, lactate production, and lactate secretion. These proteins
include glucose transporters (GLUT1-4), hexokinase 2 (HK2),
glyceraldehyde-3- phosphate dehydrogenase (GAPDH), 6-
phosphofructo-1-kinase (PFK1), aldolase (ALDO), triose-phosphate
isomerase (TPI), phosphoglycerate kinase 1 (PGK1), phosphoglyc-
erate mutase (PGM), enolase 1 (ENO1), pyruvate kinase (PKM2), lactate
dehydrogenase (LDHA) and monocarboxylate transporters (MCTs).
There is substantial evidence regarding the importance of aberrant
expression of oncomiRs and tumor suppressor miRNAs targeting key
players in aerobic glycolysis to give proliferation, growth, and invasion
advantages to cancer cells (Figure 1). Such changes in miRNA activity
reflect a mechanism by which cancer cells bypass checkpoints that
determine thresholds of biosynthetic enzyme activities.
In addition to miRNAs directly targeting genes involved in cancer cell
glycolysis, summarized in Table 1, several indirect mechanisms have
been reported for miRNA-mediated regulation of glycolytic genes.
Horie et al. [17] showed that forced expression of miR-133 decreases
GLUT4 expression by directly targeting Kruppel-like factor 15 (KLF15)
in cardiomyocytes. KLF15 is a transcription factor required for GLUT4
transcription. Also, miR-155 was reported to upregulate HK2 through
signal transducer and activator of transcription 3 (STAT3) activation, as
well as through miR-143 repression by targeting CCAAT-enhancer-
binding protein b (C/EBPb). Moreover, miR-143 was found to target
HK2 directly, linking inflammatory miR-155-related signaling with
cancer-associated changes in metabolism [18,19]. PKM is one of the
rate limiting enzymes in glycolysis. While PKM1 expression was shown
to be active in normal cells, cancer cells switch PKM1 to the tumor-
associated PKM2. Also, some miRNAs were reported to regulate pol-
ypyrimidine tract-binding protein 1 (PTB-1), which processes PKM
transcripts and is involved in PKM1 to PKM2 conversion in tumor cells.
These miRNAs, including miR-1, miR-124, miR-133b, miR-137 and
miR-340 were shown to directly inhibit cancer cell proliferation and
may also explain the repressed PTB-1 expression associated with
tumor progression in vivo [20e24].
Although several decades have passed since the first report on cancer
metabolism, with many studies since, a definitive mechanism un-
derpinning the Warburg metabolic shift has remained obscure.
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remains to be fully elucidated.
3. INTER-CONNECTION BETWEEN AEROBIC GLYCOLYSIS AND
MITOCHONDRIA
Whilst glycolysis accounts for the generation of almost two thirds of the
ATP required for tumor cells, in most cancer cells mitochondria are still
functional and generate the remaining energy requirements [92].
Mitochondria also contribute to pivotal roles in controlling anaplerotic
and cataplerotic pathways within cancer cells. Indeed, several roles for
mitochondria in carcinogenesis, other than ATP production for cellular
demands, have been established [93]. As a result, functions including
hypoxia resistance, apoptosis escape, reactive oxygen species (ROS)
control, and bio-synthetic contributions are attributed to mitochondria.
Mutations in mitochondrial TCA cycle genes, encoded by nuclear DNA,
were found in various types of cancers. Mutational inactivation of these
enzymes contributed to a metabolic shift through direct adaptation to
decreased OXPHOS or, alternatively, by epigenetic modification caused
by cytosolic and mitochondrial accumulation of oncometabolites such
as 2-hydroxyglutarate (2HG) [94e98].
Studies of miRNA localization from nucleus to mitochondria have led to
the discovery of mitochondria-related miRNAs (mitomiRs). A consid-
erable body of literature demonstrated the miRNA contributions to
every aspect of mitochondrial metabolism, respiration, and dynamics
[99]. Additionally, ROS generated within mitochondria were found to be
strictly regulated by several miRNAs (reviewed in [100]). miRNAs that
regulate tricarboxylic acid (TCA) cycle transcripts include miR-183,
miR-210 and miR-734a, which target isocitrate dehydrogenase
(IDH), succinate dehydrogenase (SDH), and malate dehydrogenase
(MDH), respectively [101e103] (Figure 1). Moreover, several electron
transport chain components are reportedly regulated by miRNAs. For
instance, miR-338 and miR-181c downregulate cytochrome c oxidase
complex COX4 and COX1, respectively. Hypoxically regulated miR-210
represses iron-sulfur cluster scaffold (ISCU) and COX10 translation
[104e106]. Glutaminase (GLS) is a rate-limiting enzyme in glutamine
metabolism which converts glutamine to glutamate. An increasing
number of reports revealed cooperation of c-Myc and p53 with several
miRNAs such as miR-23a/b, miR-125b, miR-30 and miR-504 in
modulating GLS activity [107]. Based on these reports, it is clear that
miRNAs target both nuclear mRNAs and mitochondrial mRNAs.
Moreover, the Crabtree effect, originally identified in fermenting yeast,
enables some cancer cells to switch between glycolysis and OXPHOS
in spite of functional mitochondria and also challenges the “purely
glycolytic cancer cell” paradigm. The Crabtree effect is considered to
be a short-term and reversible mechanism and an adaptive response
of mitochondria to the heterogeneous microenvironment of cancer
cells [108]. Hence, there is still a need to fully determine whether
changes in mitochondrial functionality, mediated by several miRNAs,
contribute to cellular transformation. Otherwise it may be considered a
secondary phenomenon, which arises from changes in cell glycolysis
and/or other signaling pathways also regulated by miRNAs.
4. HYPOXIA AND GLYCOLYSIS
Hypoxia is a common feature in proliferating solid tumors. In normal
cells, hypoxia leads to cellular adaptation, or p53-dependent apoptosis
and cell death. However, cancer cells acquire mutations in p53 and
other genes, along with changes in their metabolic pathways in order
to survive and even proliferate under hypoxic stress. A key mediator of
responses to hypoxia is hypoxia-inducible factor-1 (HIF-1), access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 99
Figure 1: miRNAs targeting glycolytic and mitochondrial enzymes.
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Table 1 e Summary of miRNAs directly targeting glycolytic enzymes and
transporters.
Gene miRNAs Diseases References
GLUT1 miR-495, miR-1291,
miR-130b, miR-199a,
miR-138, miR-150,
miR-532, miR-301a,
miR-19a/b, miR-22,
miR-132, miR-218,
miR-340, miR-541
Renal Cell Carcinoma, Glioma,
Breast Cancer, Prostate Cancer,
Bladder Cancer, Oral Squamous Cell
Carcinoma, Glioblastoma
Multiforme
[25e33]
GLUT2 miR-143 e [34]
GLUT3 miR-195, miR-106a Bladder Cancer, Glioblastoma [35,36]
GLUT4 miR-223, miR-93,
miR-150, miR-192,
miR-106b
Cardiomyocytes, Polycystic Ovary
Syndrome, Diabetes Mellitus
[37e40]
HK1 miR-138 Head and Neck Squamous Cell
Carcinoma
[41]
HK2 miR-34a, miR-143,
miR-125a/b, miR-
497, miR-181b/c,
miR-98, miR-4458,
miR-199a
Colorectal Cancer, Head and Neck
Squamous Cell Carcinoma, Breast
Cancer, Lung Cancer, Glioblastoma,
Hepatocellular Carcinoma, Chronic
Lymphocytic Leukemia, Primary
keratinocytes, Osteocarcinoma,
Prostate Cancer, Gastric Cancer
[18,41e53]
GPI miR-34a, miR-302b,
miR-17, miR-200
family
Colorectal Cancer, Primordial Germ
Cells, Breast Cancer
[42,54,55]
PFK miR-520, miR-320a,
miR-106b, miR-26b,
miR-206
Hepatocellular Carcinoma, Lung
Adenocarcinoma, Renal Cell
Carcinoma, Osteosarcoma, Breast
Cancer
[56e61]
ALDOA miR-34c, miR-122,
miR-15a, miR-16-1
Emphysematous Lung,
Hepatocellular Carcinoma,
Leukemia, Lung Cancer
[62e65]
GAPDH miR-644a Prostate Cancer [66]
TPI1 miR-15a, miR-16-1,
miR-107, miR-195
Leukemia, Renal Cell Carcinoma,
Lung Cancer, Bladder Cancer
[63,65,67,68]
PGK1 miR-107, miR-29a,
miR-1256, miR-17-92
cluster
Renal Cell Carcinoma, Prostate
Cancer, Lung Cancer, Pancreatic
Cancer, Squamous Cell Lung
Carcinoma
[67,69e71]
PGM Let-7g, miR-29a, miR-
33b, miR-21
Primary Human Hepatocytes, Lung
Cancer, Renal Cell Carcinoma
[60,70,72,73]
ENO1 miR-17-92 cluster,
miR-29a
Lung Cancer [70,71]
PKM2 miR-34a, miR-122,
miR-133a/b, miR-
326, miR-99a, miR-
128
Colorectal Cancer, Hepatocellular
Carcinoma, Squamous Cell
Carcinoma of Tongue, Glioblastoma,
Type 2 Diabetes, Prostate Cancer
[42,74e77]
LDHA miR-375, miR-24,
miR-23a, miR-210,
miR-30a, miR-34a/c,
miR-374a, miR-383,
miR-4524a/b, miR-
369, miR-410, miR-
590
Maxillary Sinus Squamous Cell
Carcinoma, Acute Myocardial
Ischemia, Breast Cancer, Colorectal
Cancer, Hypoxia-Induced
Cardiomyocytes Dysfunction,
Ovarian Cancer, Cervical Cancer,
Gestational Diabetes Mellitus, Type2
Diabetes
[78e88]
MCTs miR-29a/b, miR-124,
miR-376a-5p, miR-
495
Pancreatic b Cells,
Medulloblastomas, Type2 Diabetes
[89e91]transcription factor that plays a pivotal role in responding to decreased
oxygen levels, initiating hypoxia-related processes such as OXPHOS
repression and induced glycolysis [109].
Although prolyl-4-hydroxylase (PHD) and factor inhibiting HIF-1 (FIH-1;
also known as HIF1AN) dependent regulation of HIF-1 is primarily
thought to be the sole mechanism of HIF-1 regulation [110] it is now
clear that hypoxia influences miRNA biogenesis and these miRNAs can
regulate HIF-1a and HIF-1b expression [111]. HIF-1a is also regulatedMOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. This is an open a
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regulation of HIF-1a could also be a consequence of activating the
mechanistic target of rapamycin (mTOR) signaling pathway in cancer
cells. Many miRNAs, such as miR-99a, were shown to repress HIF-1a
expression by targeting mTOR [76]. The abnormal activation of HIF-1
under normoxia could alternatively be a result of changes in cancer-
associated genes. Such tumourigenic mutations include loss of func-
tion in tumor suppressors such as P53, phosphatase and tensin ho-
molog (PTEN) [113], Von Hippel-Lindau (VHL) [114], LKB1 [115],
promyelocytic leukemia protein (PML) [116], and tuberous sclerosis
proteins (TSC1/TSC2) [117] along with mutational activation of onco-
genes such as Ras [118], V-Src [119], phosphoinositide 3-kinase
(PI3K) [120], and human epidermal growth factor receptor 2 (Her2/
Neu) [121]. PKM2 was also reported to enhance HIF-1 transcription,
through binding to its promoter, and promote HIF-1 stabilization by
inhibiting PHD interactions [122]. Mitochondria also act as both targets
and effectors of HIF-1 activation [100]. To adapt to a hypoxic micro-
environment and acquire lethal cancer characteristics, HIF-1 activation
leads to a range of physiological responses [123]. At the transcriptional
level, HIF-1a activates a variety of genes following translocation into
the nucleus, dimerization with HIF-1b and binding to hypoxia response
elements (HREs) upstream of target genes. Besides HRE-dependent
responses, HIF-1a interacts with other signal transduction pathways
including Notch [124], Wnt [125] and c-Myc [126].
Activated HIF-1 is directly and indirectly associated with increased
expression of virtually all glycolytic transporters and enzymes [123].
Moreover, HIF-1 affects mitochondria through various mechanisms
and stimulates glycolysis indirectly by supressing mitochondrial
oxidative metabolism, which enables HIF-1 to function as a switch
between glycolysis and OXPHOS [127]. HIF-1 represses mitochondrial
pyruvate dehydrogenase (PDH) activity [109], which is a gate-keeping
enzyme feeding the TCA cycle by converting pyruvate to acetyl-CoA.
HIF-1 suppresses PDH expression by actively upregulating pyruvate
dehydrogenase kinase (PDK1), a PDH suppressor [128]. By such
regulation, pyruvate is converted to lactate, cytosolic NADH is re-
oxidized and glycolysis is continued. As a consequence, PDH sup-
pression by activated HIF-1 protects cells from increased ROS
generated within mitochondria [129]. In addition, HIF-1 regulates
mitochondrial function in response to oxygen by mediating a subunit
switch in COX4. HIF-1 induces COX4I2 subunit expression under
hypoxic conditions, while the normoxic COX4I1 subunit is down-
regulated through HIF-1-mediated activation of LON, a mitochondrial
protease. This subunit switch optimizes the efficiency of respiration in
response to hypoxia by influencing H2O2 levels in an oxygen-
dependant manner [127]. Zhao et al. [130] showed that HIF-1a
upregulates TKT and TKTL2, two transketolase enzymes of the pentose
phosphate pathway, to elevate the ribose production required for
nucleic acid anabolic pathways.
Thus far, no mutations within the HIF-1 genes have been associated
with its activation or related regulation of glucose metabolism. How-
ever, aberrant HIF1 activity has proved to be important in the initiation
and maintenance of some tumors [112].
Hypoxia is a significant mediator of miRNA biosynthesis, at both the
transcriptional and post-transcriptional levels [131]. A recently iden-
tified subset of miRNAs are known as “hypoxia regulated miRNAs”
(also termed hypoxiamiRs or HRMs). Hypoxia regulates hypoxiamiRs in
either a HIF-1 dependent or independent manner [132]. First reported
by Kulshreshtha et al. [111], hypoxia is capable of upregulating miRNA
expression (Table 2 and Figure 2). Among these hypoxia-inducible
miRNAs, miR-210 and miR-26 were found to have dynamic recruit-
ment of HIF-1 to their promoters. Upon activation, HIF-1a translocatesccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 101
Table 2 e Summary of associations between miRNAs and hypoxia.
miRNA Disease/cell line Regulation of HIF/
mechanism
Regulation of
miRNA by Hypoxia
References
miR-17-92 cluster Lung Cancer, Cervical Adenocarcinoma, Inflammation, Colon
Cancer, Brest Cancer, Hepatocarcinoma
Downregulation/targeting HIF-
1a and HIF-2
Downregulation [71,134,136,159,160,163,166]
miR-15b Hemophilia, Nasopharyngeal Carcinoma Downregulation/targeting HIF-2 Downregulation [166,167]
miR-16 Nasopharyngeal Carcinoma NA Downregulation [166]
miR-19a Oral Squamous Cell Carcinoma, Human Atherosclerotic Lesions NA Downregulation/
Upregulation
[135,168]
miR-20a/b Nasopharyngeal Carcinoma, Lung Cancer Downregulation/targeting HIF-
1a and HIF-2a
Downregulation [71,166]
miR-21 Breast Cancer, Prostate Cancer Upregulation Upregulation [111,150,169]
miR-22 Clear Cell Renal Cell Carcinoma, Colorectal Cancer, Heart muscle,
Oral Squamous Cell Carcinoma
Downregulation/targeting HIF-
1a
Upregulated/
Downregulated
[132,135,170,171]
miR-23a/b Colorectal Cancer, Breast Cancer NA Upregulated [111,172]
miR-24 Colorectal Cancer, Breast Cancer NA Upregulated [172]
miR-26a/b Nasopharyngeal Carcinoma, Colorectal Cancer, Breast Cancer NA Upregulated/
Downregulated
[166,172]
miR-27a/b Heart Muscle, Colorectal Cancer, Breast Cancer NA Upregulated [132,172]
miR-30 b/d/e Oral Squamous Cell Carcinoma, Colorectal Cancer, Breast Cancer,
Nasopharyngeal Carcinoma
NA Downregulation/
Upregulated
[135,166]
miR-29b Oral Squamous Cell Carcinoma NA Downregulated [135,172]
miR-31 Colorectal Cancer, Human Corneal Epithelial Keratinocytes, Oral
Squamous Cell Carcinoma
Upregulation/targeting FIH1 Upregulated [135,145,147,173,174]
miR-33a Melanoma Downregulation/targeting HIF-
1a
NA [175]
miR-93 Colorectal Cancer, Breast Cancer NA Upregulation [111]
miR-99a Type 2 Diabetes Downregulation/targeting HIF-
1a
NA [76]
miR-101 Oral Squamous Cell Carcinoma NA Downregulation [135]
miR-103 Colorectal Cancer, Breast Cancer NA Upregulated [111]
miR-106b Colorectal Cancer, Breast Cancer NA Upregulated [111]
miR-107 Ischemic Heart Disease, Colorectal Cancer, Colorectal Cancer,
Breast Cancer
Downregulation/targeting HIF-
1b
Upregulation [111,151,152]
miR-122a Oral Squamous Cell Carcinoma NA Downregulation [135]
miR-125b Colorectal Cancer, Breast Cancer NA Upregulated [111]
miR-128 Prostate Cancer Downregulation/targeting HIF-
1a
NA [77]
miR-135b Prostate Cancer, Breast Cancer Upregulation/targeting FIH-1 NA [142,176]
miR-138 Clear Cell Renal Cell Carcinoma, Ovarian Cancer Downregulation/targeting HIF-
1a
NA [177,178]
miR-141 Oral Squamous Cell Carcinoma NA Downregulation [111]
miR-155 Cervical Adenocarcinoma, Nasopharyngeal Carcinoma Downregulation/targeting HIF-
1a
Upregulation [159,166]
miR-181a/b/c Colorectal Cancer, Breast Cancer, Nasopharyngeal Carcinoma, Heart
Muscle
NA Upregulated/
Downregulated
[111,132,166]
miR-184 Glioma Upregulation/targeting FIH-1 NA [146]
miR-186 Oral Squamous Cell Carcinoma, Gastric Cancer Downregulation/targeting HIF-
1a
Downregulation [135,179]
miR-192 Colorectal Cancer, Breast Cancer NA Upregulated [111]
miR-195 Hypoxic Chondrocytes, Colorectal Cancer, Breast Cancer Downregulation/targeting HIF-
1a
Upregulation [111,180]
miR-197 Oral Squamous Cell Carcinoma NA Downregulation [135]
miR-199a/b Ovarian Cancer, Sickle Cell Disease, Lung Cancer exposed to
arsenic, Heart muscle
Downregulation/targeting HIF-
1a and HIF-2a
Downregulation [132,137,181,182]
miR-204 Pulmonary Arterial Hypertension Downregulation/targeting HIF-
1a
NA [183]
miR-206 Pulmonary Arterial Hypertension Downregulation/targeting HIF-
1a
NA [149]
miR-210 Cervical Cancer, Head and Neck Paragangliomas, Hypotriploid
Human Kidney Cell Line, Ischemia, Breast Cancer, Nasopharyngeal
Carcinoma, Oral Squamous Cell Carcinoma, Heart Muscle,
Colorectal Cancer, Breast Cancer
NA Upregulation [111,132,135,154,166,184
e186]
miR-213 Colorectal Cancer, Breast Cancer NA Upregulation [111]
miR-361 Umbilical Vein Endothelial Cells (HUVEC) Downregulation/targeting HIF-
1a
Downregulation [187]
miR-374 Oral Squamous Cell Carcinoma, Breast Cancer Upregulation/targeting TXNIP Downregulation [135,188]
miR-422b Oral Squamous Cell Carcinoma NA Downregulation [135]
miR-424 Ovarian Cancer, Oral Squamous Cell Carcinoma Upregulation/targeting CUL2 Downregulation [134,135,156]
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Table 2 e (continued )
miR-429 Human Endothelial Cells Downregulation/targeting HIF-
1a
Upregulation [165]
miR-494 Lung Cancer NA NA [157]
miR-519c Hepatic Cancer Downregulation/targeting HIF-
1a
NA [189]
miR-565 Oral Squamous Cell Carcinoma NA Downregulation [135]to the nucleus and targets HREs of downstream genes, including
miRNA encoding genes. Interestingly, hypoxia is also associated with
miRNA downregulation. In that regard, the miR-17e92 cluster was
downregulated by hypoxia in p53 wild type cells [133]. Similarly, Lei
et al. [134] reported miR-20b upregulation in HIF1-knockdown cells.
Other hypoxia-suppressed miRNAs are listed in Table 2. Nevertheless,
contrasting reports, with miRNAs such as miR-26 and miR-19,
demonstrate that hypoxia-dependent regulation of miRNAs is cell
type and microenvironment dependent [111,135]. Among down-
regulated hypoxiamiRs, HIF-1 was shown to downregulate miR-17 and
miR-199a [136,137]. HIF-1 also regulates miRNA expression indirectly
by mediating the expression of other transcription factors, examples
being activation of miR-10b by HIF-1-dependent TWIST1 expression
and regulation of miR-20a/b through vascular endothelial growth factor
A (VEGFA) targeting by HIF-1 [138,139]. Beside miRNAs directly
regulated by hypoxia, it is evident that hypoxia is post-transcriptionally
involved in the regulation of hypoxiamiR biogenesis, processing and
function in both a HIF-dependent and independent manner. It was
shown that hypoxia accelerates Ago2 assembly to RISC and its
translocation to stress granules by upregulating Ago2 prolyl-
hydroxylation and increasing its endonuclease activity [140]. More-
over, HIF-1 regulates expression of the prolyl 4-hydroxylase, alpha
polypeptide I (P4HA1) by regulating miR-124 expression [141]. In fact,
stress granule formation increased in a hypoxia-dependent manner.
Nonetheless, ADP-ribosylaton of Ago2 in response to oxidative stress is
another mechanism that eventually leads to relief of miRNA-mediated
repression. Interestingly, it was reported that some miRNA maturation
that is not dependent on Dicer activity [142], might be processed by the
endonuclease activity of Ago2, the levels of which are induced by
hypoxia. Accordingly, Dicer was found to be downregulated by hypoxia,
while miR-451 was upregulated [143,144].
HIF-1a may be directly targeted by miRNAs in various diseases,
including cancer (Table 2). Besides direct translational repression,
some miRNAs inhibit other factors that modulate HIF-1 expression and
stability. As FIH-1 inhibits the transcriptional activation of HIF-1a;
miRNAs that suppress FIH-1, such as miR-31, miR-135b, and miR-
184, result in HIF-1 activation [142,145,146]. FIH-1 was also shown
to regulate cell metabolism through reducing glycogen and attenuating
AKT signaling [147]. miR-92-1 supresses HIF-1 degradation by tar-
geting pVHL [148]. miR-206 targets the HIF-1/FHL-1 pathway on
pulmonary artery smooth muscle cells to promote hypertension [149].
Increased expression of miR-21 was shown to increase HIF-1a and
VEGF expression in prostate cancer possibly through a PTEN-
dependant pathway [150]. miR-107 downregulates mRNA and pro-
tein levels of HIF-1b in endothelial progenitor cells while over-
expression of HIF-1b also blocks the effects of miR-107 [151,152].
miR-185 targets HIF-2a transcripts and, thus, indirectly moderates
HIF-1 expression and stability [153].
Feedback loops have been reported in the miRNA regulation of HIF-1.
miR-210 forms a positive feedback loop with HIF-1 where hypoxia-MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. This is an open a
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et al. [154] showed that miR-210 targets glycerol-3-phosphate de-
hydrogenase 1 like (GPD1L), a HIF-1 regulator, and overexpression of
miR-210 results in decreased HIF-1 proline hydroxylation and
increased accumulation during hypoxia. What’s more, HIF-1 directly
induces miR-210 expression, which then causes synthesis of cyto-
chrome c oxidase 2/1 (SCO2/1) protein activation and enhanced TCA
cycle function [155]. Hypoxia was shown to induce C/EBP levels,
which, in turn, increase PU1 activation and binding to the miR-424
promoter to induce its expression. Upregulated miR-424 inhibits
cullin 2 (CUL2) and leads to HIF-1 stabilization and nuclear trans-
location [156]. Overexpression of miR-494 and miR-21 significantly
increases Akt phosphorylation and subsequently induces HIF-1 activity
[150,157]. Recent evidence that the activities of non-coding RNAs,
including oncogenic miR-21, can be manipulated by small molecules
suggests that such processes may be druggable [158].
As a predominant oncomiR, the miR-17e92 cluster has been heavily
investigated for its association with hypoxia. Bertozzi et al. [159]
showed that miR-17-5p reduced HIF-1a at low camptothecin expo-
sure. miR-17 and miR-20a also target the 30UTR of HIF-1 and HIF-2 in
primary human macrophages [160]. All members of this cluster were
shown to directly target HIF-1 in lung cancer [71]. miR-17 and miR-
20a were downregulated by HIF-1 through a transcriptional and HIF-
1b-independent manner and by downregulating c-Myc expression
[136]. miR-20a is a hypoxia-responsive miRNA that targets HIF-1 in
breast cancer, lung adenocarcinoma, colorectal cancer, and endo-
metriotic stromal cells [71,138,160e162]. In the paralogous miR-
106aw363 cluster, miR-20b is known to target HIF-1 in hepatocellular
carcinoma (HCC) and breast cancer cells [163,164]. Also, chromatin
immunoprecipitation analyses revealed that miR-20b prevents HIF-1
binding to the VEGF promoter and, thus, modulates VEGFA expres-
sion [163].
Aberrant expression of miRNAs, which can result from hypoxia
encountered during tumor progression, may play a critical role in HIF-1
regulation and altered downstream effects (Figure 2). Interestingly,
some miRNAs that target HIF-1 were also reported to be modulated by
hypoxia in both a HIF-dependent and independent manner. However,
some anomalies regarding hypoxiamiRs and miRNAs that regulate HIF-
1 still exist. For instance, Bartoszewska et al. [165] showed that HIF-1
is a direct target of miR-429 in HUVEC cells and is induced during
hypoxia. However, Sun et al. [157] showed that overexpression of miR-
429 increases HIF-1a expression, under both hypoxia and normoxia,
and couldn’t find a miR-429 target sequence in the 30UTR of HIF-1a in
liver cells. These inconsistencies likely depend on cellular context and
experimental conditions. Moreover, as HIF is mainly post-
translationally regulated, miRNA activity may be largely redundant in
some systems. Table 2 summarizes the associations between hypoxia
and miRNAs in different cancers. It has been proposed [92] that the
observed Warburg effect is entirely attributable to the in vivo tumor
hypoxia and is, in fact, a manifestation of the Pasteur Effect.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 103
Figure 2: Interconnections between the drivers and suppressors of glycolysis, and the role of miRNAs in these networks. Proteineprotein interactions identified using
String V10.0. Solid blue lines indicate protein activation while solid red lines indicate protein inhibition. Dotted blue and red lines represent transcription factor-mediated activation
or inhibition of the miRNAs, respectively. miRNAs in pink boxes repress gene expression, while those in orange and blue boxes indicate miRNAs that are inhibited or activated by
the transcription factors, respectively. Specific miRNAs present in both the pink boxes and either the orange or blue boxes, may represent feedback loops in particular cellular
contexts.
Review5. METABOLIC CONSEQUENCES OF MIRNA ASSOCIATIONS
WITH DRIVER MUTATIONS AND TRANSFORMATION
While oncoproteins and tumor suppressor proteins are well-known
for their roles in regulating cellular processes such as cell prolifer-
ation, they are also capable of affecting cancer cell metabolism.
Activation of certain oncogenic signals is important for stimulating
glycolysis. Various mutations in different oncogenes and tumor
suppressors show that cancer cells alter metabolism to adapt to
their microenvironment [190]. These fundamental genes include
oncogenes such as KRAS, MYC, AKT, and MTOR, along with their
inhibitors (PTEN and TSC1/2) and activator (EGFR). They also include
tumor suppressor genes such as TP53, along with its negative
regulator murine double mutant 2 (MDM2) and metabolic effector
TP53-induced glycolysis and apoptosis regulator (TIGAR). Sirtuins
are further regulatory molecules that can act both as oncogenes and
tumor suppressors and will be discussed later. Accumulating evi-
dence highlights the association of miRNAs with oncogenes and
tumor suppressors. Some cancer associated genes, such as HIF1,
MYC and TP53, regulate both the expression and functions of some104 MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. TmiRNAs and are regulated by miRNAs. Table 5 and Figure 2 sum-
marize recent findings on miRNA-mediated regulation of oncogenes
and tumor suppressors.
5.1. KRAS proto-oncogene
The KRAS oncogene features as an early mutation in up to 45% of
colorectal tumors, notable because it can drive many hallmarks of
cancer [191]. KRAS-mediated transformation is linked with mito-
chondrial respiratory dysfunction and elevated NADPH oxidase (NOX)-
mediated ROS generation [192,193]. Wang et al. [194] postulated that
oncogenic KRAS influences complex I activity in the electron transport
chain, most likely by downregulating complex I assembly factor protein
(NDUFAF1) and, as a consequence, induces mitochondrial dysfunction.
However, additional oncogenic signals and/or loss of tumor suppres-
sors, including dysregulated miRNAs, are required for tumourigenesis.
Unsurprisingly, KRAS is a target of multiple miRNAs, including let-7,
miR-96, miR-134 and miR-143 (Summarized in Table 5). These
miRNAs affect cancer cell metabolism, cell cycle arrest, apoptosis, cell
migration and invasion, especially by modulating RAS/MAPK signaling
(Figure 2)his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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KRAS is frequently mutated in human neoplasia including pancreatic,
colorectal and lung cancer. The oncogenic KRASG12V variant, which
leads to higher KRAS activity, was reported to be the most frequent
mutation. However, despite low KRAS mutation frequency in glio-
blastoma and breast cancer cells, activation of the wild-type KRAS
pathway is common in these cancers. Also, sequence variants in the
KRAS 30UTR (rs712) were found in gastric cancer, colorectal cancer,
papillary thyroid cancer, breast cancer, and non-small cell lung cancer,
which disrupt let-7 binding site and subsequent miRNA-mediated
downregulation [195e199].
The expression of some miRNAs such as let-7, miR-126, miR-200c,
miR-193b, and miR-4689 was found to be lower in KRAS mutant
cells, as compared to tumors expressing wild-type KRAS [199e203],
confirming the context dependent activity of miRNAs, even in regu-
lating KRAS itself. Kopp et al. [200] reported that in breast cancer cells
harboring the KRASG13D mutation, miR-200c targets KRAS transcripts
and inhibits proliferation and cell cycle progression, while in KRAS wild
type cells miR-200c affects proliferation through other targets. Despite
different miR-126 expression levels in KRAS mutant and wild type
colon cancer cells, Hara et al. [201] showed that over-expression of
miR-126 does not alter KRAS expression and function. In contrast, Jiao
et al. [204] showed KRAS regulation by miR-126 in pancreatic cancer.
Such variations suggest that the activity of some miRNAs is subjected
to changes through both transcriptional and post-transcriptional pro-
cesses during tumourigenesis. Examples are erythropoietin-producing
hepatoma receptor A1 (EphA1) upregulating let-7 in multiple myeloma
[205], EVI1 suppressing miR-96 in pancreatic ductal adenocarcinoma
[206], KLF4 downregulating miR-134 in glioblastoma [207] and MYC
associated factor X (MAX) inhibiting miR-193a in breast cancer [208].
Therefore, coordinated suppression of miRNAs, as is found in various
cancers, would not only influence oncogenic KRAS activity but may
also influence other genes involved in KRAS-related signaling to
cooperatively initiate tumourigenesis, including genes in metabolic
pathways.
5.2. MYC proto-oncogene
Overexpression of the c-MYC proto-oncoprotein plays pivotal roles in
sustaining the transformed phenotype of most cancer cells [209]. The
discovery that LDHA is among 20 putative targets of c-MYC provided
evidence that c-MYC directly regulates glycolysis. Since then, other
glycolytic genes including GLUTs, GAPDH, PGK, HK2, ENO1, PGM,
PKM2, and MCTs are also reportedly induced by c-MYC [210].
Along with its role in glycolysis, c-MYC was found to regulate mito-
chondrial biogenesis, respiration, and function [211]. Upregulation of
some nuclear genes that encode proteins for mitochondrial function,
mitochondrial DNA replication and transcription of mitochondrial DNA
are known to be direct consequences of c-MYC overexpression [212].
c-MYC also contributes to mitochondrial biogenesis and gives rise to
the synthesis of acetyl-CoA and fatty acid biosynthesis required for
cancer cell proliferation. In parallel, c-MYC upregulates the glutamine
catabolism required for biosynthetic processes by inducing GLS and
the glutamine transporters, ASCT2 and SLC7A25 [213,214]. Overall,
while c-MYC enhances glycolysis and consequently depletes pyruvate
required for mitochondrial OXPHOS, it also confers the ability for cancer
cells to utilize non-glucose substrates and maintain mitochondrial
respiration to support cancer cell proliferation and progression.
c-MYC cooperates with HIF-1, or acts independently, to regulate
glycolysis and OXPHOS [215]. In normal cells, MYC enhances glycolytic
flux to OXPHOS. However, in cancer cells, c-MYC cooperates with HIF-
1 and PKM2 to upregulate glycolysis and provide adequate metabolic
intermediates for biomass synthesis [216]. While upregulation of HIF-MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. This is an open a
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regulates glycolytic genes independently under normal oxygen tension.
In addition, while HIF-1 upregulates PDK1 under hypoxia, c-MYC co-
operates with HIF-1 to further upregulate PDK1 and, thus, amplifies the
hypoxic response. Therefore, under normoxia, c-MYC enhances
glycolysis, but it cooperates with HIF-1 to upregulate PDK1 and reduce
mitochondrial respiration under hypoxic conditions [217]. Intriguingly,
elevated ENO1 was shown to form a negative feedback loop with
activated c-MYC. c-MYC-induced ENO1 increases the expression of
MBP1, a transcription factor, and suppresses c-MYC expression [218].
c-MYC both regulates miRNA expression and is, in turn, controlled by
them (Tables 3 and 5). Several miRNAs have been shown to modulate
c-MYC expression by different mechanisms (Figure 2). Let-7a, miR-22,
miR-33b, miR-34a, miR-130a, miR-145, and miR-155 were found to
suppress c-MYC after binding with canonical target sequences in the
c-MYC 30UTR [219e226]. miR-24 binds to a seedless, but highly
complementary, sequence while miR-18-5p and miR-774 bind to the
protein coding region of c-MYC mRNA [221,227,228]. Some other
miRNAs, such as miR-363-3p act more indirectly. In HCC, miR-363-3p
destabilizes c-MYC through targeting USP28, a ubiquitin protease of
MYC, and promoting the degradation of pre-existing c-MYC protein
[229]. Several reports indicate a coordinated and reciprocal relation-
ship between c-MYC and miRNA expression levels. For instance, Liao
et al. [228] showed a negative feedback and auto-regulatory role for c-
MYC levels, as monitored by miR-185-3p. They confirmed that miR-
185-3p is a genuine transcriptional target of c-MYC but also that
miR-185-3p inhibits c-MYC translation by targeting the coding region
of c-MYC transcripts.
c-MYC activates or represses a variety of genes, including miRNA
genes, mainly through interactions with different complexes and
proteins. c-MYC supresses MIR122 gene transcription in liver tumors
through association with a conserved promoter region upstream of the
MIR122 gene. It also downregulates hepatocyte nuclear factor 3-beta
(HNF3b), which normally activates miR-122 and enhances its stability
[230,231].
miR-122 was reported to supress c-MYC expression indirectly by
targeting E2F1 and TFDP2 (E2F dimerization partner 2) mRNA [232]. In
addition, feedback regulation was reported for miR-17-5p/c-MYC/E2F
in some cancers, including breast and prostate [233]. Nadiminty et al.
[234] reported a LIN28/let-7/c-MYC loop that plays an important role in
some cancers. Relief of c-MYC repression occurs when LIN28, a highly
conserved RNA-binding factor, binds let-7 precursors and inhibits
miRNA maturation [235]. There is a direct relationship between c-MYC,
its dimerization partner, MAX, and the expression of some miRNAs
such as let-7a and miR-22 [225,236]. c-MYC can also transcriptionally
activate some miRNAs, including the miR-17-92 cluster, through
interaction with MAX protein at the polycistronic promoter region
[233,237]. Ting et al. [225] showed that increased miR-22 limits the
amount of MAX protein available for c-MYC binding by directly tar-
geting it and, therefore, affects the expression of downstream targets
of the c-MYC/MAX complex. In contrast, interaction of c-MYC with MIZ-
1 represses expression of some c-MYC target genes through
displacement of p300 co-activator protein [238]. There is also a
miRNA/c-MYC negative feedback loop in HCC with miR-148a-5p
directly targeting c-MYC and, as previously mentioned, miR-363-3p
indirectly destabilizing c-MYC by targeting ubiquitin specific pepti-
dase 28 (USP28) [229]. Other miRNAs that are repressed transcrip-
tionally and post-transcriptionally by c-MYC are summarized in
Table 3.
The activation of c-MYC alone is unable to transform cells. Therefore,
there is cooperation between oncogenic partners, such as RAS, andccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 105
Table 3 e Summary of miRNAs regulated by the transcription factor MYC.
miRNA Regulation Disease/cells References
miR-2b Upregulation Drosophila S2 Cells [242]
miR-277 Upregulation Drosophila S2 Cells [242]
miR-92 Upregulation Neuroblastoma, Burkitt
Lymphoma
[233,243]
miR-106a Upregulation Neuroblastoma, Burkitt
Lymphoma
[233,243]
Let-7a/c Up/Downregulation Neuroblastoma, Burkitt
Lymphoma, Breast Cancer,
Prostate cancer
[234,235,243,244]
miR-17 Upregulation Neuroblastoma, Burkitt
Lymphoma
[233,243]
miR-93 Upregulation Neuroblastoma [243]
miR-99 Upregulation Neuroblastoma [243]
miR-221 Upregulation Neuroblastoma [243]
miR-18 Upregulation Burkitt Lymphoma [233]
miR-19 Upregulation Burkitt Lymphoma [233]
miR-20 Upregulation Burkitt Lymphoma [233]
miR-15a Downregulation Lymphoma [245]
miR-16 Downregulation Lymphoma [245]
miR-22 Downregulation Lymphoma [245]
miR-23a/b Downregulation Lymphoma, Prostate Cancer [107]
miR-26a/b Downregulation Lymphoma, Burkitt Lymphoma,
Prostate Cancer
[245e247]
miR-29 Downregulation Lymphoma, lung
Adenocarcinoma
[245,248]
miR-34 Downregulation Lymphoma [245]
miR-146a Downregulation Lymphoma [245]
miR-150 Downregulation Lymphoma [245]
miR-195 Downregulation lymphoma [245]
miR-141 Upregulation Embryonic Stem Cells,
Nasopharyngeal Carcinoma
[249,250]
miR-200 Upregulation Embryonic Stem Cells [249]
miR-429 Upregulation Embryonic Stem Cells [249]
miR-9 Upregulation Breast Cancer [251,252]
miR-185 Upregulation Non-small Cell Lung Cancer [228]
miR-122 Downregulation Hepatocellular Carcinoma [230e232]
Reviewinactivation of tumor suppressors such as p53 in c-MYC dependant
tumor development [239e241]. Hence, along with passive adaptation
of tumor cells, oncogenic mutations and transcriptional controls, such
as the reciprocal association of c-MYC with several miRNAs, enhance
the ability of cancer cells to consume non-glucose substrates and fuel
mitochondria. This may explain the inefficiency of drugs which only
target glycolysis and add another layer of complexity to therapeutic
strategies.
5.3. PI3K/AKT pathway
The PI3K intracellular signaling pathway plays a critical role in cell
apoptosis, proliferation, and protein synthesis. Its role in regulation of
glucose uptake and metabolism is equally definitive. PI3K dysregula-
tion was reported in several human cancers and several drugs tar-
geting this pathway are currently in clinical trials [253]. Activation of
PI3K leads to an upregulation of downstream effectors such as AKT
and mTOR.
The evolutionarily conserved serine/threonine kinase, AKT, was re-
ported to be one of the most prevalent and constitutively activated
onco-proteins in malignant cells [254,255]. AKT is an important
activity-dependent stimulus for cancer cell metabolism, influencing
glycolysis by both direct and indirect mechanisms. AKT plays a central
role in the regulation of cellular energy metabolism and glucose ho-
meostasis. It stimulates ATP generation by accelerating both glycolytic
and oxidative metabolism with a concomitant increase in oxygen
consumption to preserve energy. AKT activation results in ROS106 MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. Tgeneration and, therefore, contributes to tumourigenesis by inducing
mutations and facilitating tumor-promoting signaling pathways and
inducing mutations [256]. Elevated, AKT-mediated, glycolysis plays a
major role in proliferation and survival of transformed cells. AKT in-
creases glucose uptake, directly, by increasing the expression and
plasma membrane translocation of glucose transporters (GLUT1,
GLUT2, and GLUT4) [257]. It also maintains MMP and promotes the
association of HK2 with the mitochondrial outer membrane by medi-
ating HK2 phosphorylation and inhibiting glucose-6 phosphate disso-
ciation from the mitochondrial membrane [258]. This may enhance
enzymatic efficiency of the kinase, promote metabolic coupling be-
tween glycolysis and OXPHOS, increase ATP synthesis through
OXPHOS and decrease susceptibility to apoptosis [256]. Indirectly, AKT
activates PFK1 phosphorylation and activation by inducing PFK2 and
releases forkhead box O1 (FOXO)-mediated repression of glycolysis.
AKT also activates mTORC1 indirectly through phosphorylating and,
thus, inactivating TSC2, an mTOR inhibitor [259e261]. The ability of
AKT to increase glucose uptake and glycolysis in tumor cells may also
require cooperation from other cancer-associated proteins, such as c-
MYC and HIF-1. Although AKT-transformed cells show elevated levels
of amino acid and lipid transporters that are linked to cell growth,
constitutive activation of AKT renders cells dependent on an extra-
cellular glucose supply for survival [256]. Together these findings
demonstrate the coordinated regulation of glycolysis and OXPHOS by
oncogenic AKT.
AKT, which is described as “Warburg’s kinase”, provides selective
advantages to tumor cells by increasing both glycolysis and OXPHOS
[262]. Several miRNAs were reported to modulate AKT expression
directly by targeting AKT mRNA, and protein phosphorylation and/or
indirectly regulating its upstream stimuli, such as EGFR and its up-
stream repressors, such as PTEN (Figure 2).
While some miRNAs, such as miR-637 in glioma, miR-302a and miR-
29b in prostate cancer and miR-143 in bladder cancer, directly bind
the AKT 30UTR and inhibit its translation, some other miRNAs, reduce
AKT phosphorylation without affecting total AKT levels. For instance,
miR-126 reduces AKT phosphorylation by inhibiting by phosphatidy-
linositol 3-kinase regulatory subunit beta (p85b) [263e267] (Table 5).
Other proteins and regulatory factors also contribute to regulating AKT
activation in different cell types and conditions. For instance, the over-
expression of Rictor, a target of miR-34a and mTORC2 component,
causes activation of AKT in glioma stem cells [268]. Rictor activation
results in mTORC2 activation and consequently, AKT is further acti-
vated by mTORC2 mediated phosphorylation [269]. In breast cancer
cells miR-205, which is often downregulated in cancer, targets HER3
receptor transcripts and supresses the activation of AKT [270]. Protein
phosphatase 2 scaffold subunit Abeta (PPP2R1B) is another interme-
diate in AKT signal transduction, directly interacting with AKT, and is a
target of miR-200c in esophageal cancer cells [271]. Al-Khalaf and
Aboussekhra [272] showed that miR-141 and miR-146b-5p target an
RNA binding protein, AUF1, which has an important role in PI3K/AKT/
mTOR pathway regulation. AUF1 binds to and stabilizes PDK1 mRNA
and promotes AKT phosphorylation and activation. AUF1 was also
reported to negatively regulate PTEN phosphatase and activate PI3K
[273,274]. Additionally, some AKT-targeting miRNAs were shown to
regulate drug sensitivity in cancer cells, such as miR-29b and miR-
200c that influence chemotherapy responses in prostate and esoph-
ageal cancers, respectively [265,271].
However, the miRNAs that regulate AKT signaling do not act to fully
repress AKT and its mediators. Rather, they fine tune expression in a
context-specific manner. Therefore, it is likely that AKT is not exclu-
sively regulated by specific miRNAs and further, it is not surprising thathis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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some miRNAs, such as miR-153 which targets both PTEN and AKT
[275,276], play complex pleiotropic roles in regulating PI3K/AKT
signaling.
Although a number of studies have reported EGFR gene amplification in
some cancers, post-transcriptional modulation remains a significant
cause of EGFR overexpression in cancer cells (Table 5). For instance,
miR-7 was found to regulate expression of multiple effectors of the
EGFR signaling pathway, as well as directly targeting EGFR mRNA.
Zhou and Hu et al. [277] showed that miR-7 overexpression in
epithelial ovarian carcinoma (EOC) cells results in reduced expression
of EGFR without any changes in EGFR phosphorylation. A feedback
loop between miR-7 and EGFR was reported [277,278], as increased
EGFR activity results in extracellular-signal-regulated kinase (ERK)-
mediated degradation of YAN, which is a miR-7 repressor. Further,
miR-7 binds to the YAN 30UTR and represses its expression [279].
PTEN has a central role in cell cycle progression. Although mutational
loss of PTEN was reported in some cancers, epigenetic factors,
including miRNAs, also regulate PTEN expression [280] (Table 5). Due
to the unusually long 30UTR of PTEN, it contains binding sites for many
miRNAs, which can reduce its mRNA levels (including miR-32, miR-29,
miR-26a/b, miR-217, miR-486, miR-193a, miR-519d) [281e289] or
PTEN translation without affecting its mRNA levels (miR-93, miR-214,
miR-221, miR-494, miR-21) [290e296].
Furthermore, miR-185 in HCC and miR-26a in low-grade glioma alter
PTEN promoter methylation and play a subordinate role in PTEN gene
regulation by targeting DNA (cytosine-5)-methyltransferase 1 (DNMT1)
and enhancer of zeste homolog 2 histone methyltransferase (EZH2)
[282,297]. Therefore, along with direct regulation of PTEN by the
aforementioned miRNAs, several miRNAs regulate PTEN through in-
direct mechanisms. Examples include PTEN repression via miR-101
and miR-1 both targeting the PTEN activator, membrane-associated
guanylate kinase inverted 2 (MAGI-2); as well as PTEN induction
following the miR-185 targeting of PTEN silencer, DNMT1 [297e299].
High glucose was shown to affect some PTEN targeting miRNAs, such
as stimulating miR-21 levels in renal cancer or lowering miR-32 levels
in HCC, depending on the physiological status of the cells, which re-
sults in AKT activation or suppression, respectively [300,301].
PTEN dephosphorylates PIP3, generated by PI3K, to inhibit AKT acti-
vation. Suppression of PTEN, through miRNA-mediated mechanisms,
enhances AKT phosphorylation and signaling and supports cell pro-
liferation and survival [302]. PTEN inhibition also results in cystic
vestibular schwannoma development and cancer cell invasion via
induced metalloproteinase-2 (MMP-2) [303]. Transforming growth
factor beta 1 (TGF-b) mediated AKT activation is another consequence
of reduced PTEN activity [289,304]. Decreased PTEN expression was
also shown to impair p53-dependant responses in cancer cells [286].
Moreover, some miRNAs were shown to induce drug- and radio-
resistance by inhibiting PTEN. For instance, miR-21 induces dauno-
rubicin resistance in leukemia, miR-214 induces cisplatin resistance in
ovarian cancer cells and miR-221 induces TRAIL- and radio-resistance
in glioma cells by inhibiting PTEN [288,293,305]. Breast cancer me-
tastases in the brain also display increased aggression due to sup-
pression of PTEN by astrocyte exosomal miRNAs [306].
5.4. Mechanistic target of rapamycin kinase (mTOR)
Mechanistic target of rapamycin (mTOR), also known as mammalian
target of rapamycin, consists of two divergent complexes: complex 1
(mTORC1) and (mTORC2). mTORC1 acts as a metabolic hub, inte-
grating extracellular stimuli with nutrient availability and cellular en-
ergy to coordinate responses. mTORC1 is mainly involved in cellular
proliferation, translation and metabolic programming while mTORC2MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. This is an open a
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newly synthesized polypeptides [307,308].
mTOR is stimulated by loss of function of some inhibitors including
LKB1, PML, PTEN, and TSC1/2 or activation of some oncogenes such
as AKT and RAS [115,116,262,309]. Activated mTOR, in turn,
dramatically enhances the translational machinery and ribosome
biogenesis, increases cell growth in response to mitogens, growth
factors and hormones, and upregulates some transcription factors
[310]. It also activates several glycolytic enzymes such as GLUT1,
LDHA, PKM2, and HK2 [311e313]. The connection between hypoxia
and mTOR is of particular interest. Although it has been shown that
mTOR is able to induce HIF-1 translation, mTOR activity is reduced in
hypoxia, likely through negative feedback [314,315]. Hypoxia-
mediated inhibition of mTOR could be through activation of tuberous
sclerosis protein (TSC1/2) via AMPK, REDD1 or BNIP3 activation
[117,309,316,317]. However, there is also evidence that hypoxia-
mediated inhibition of mTOR is more prevalent in normal cells
compared with cancer cells [318]. Therefore, it may be concluded that
mutations in the mTOR signaling pathway account for the reduced
hypoxia-mediated mTOR inhibition. It was discovered that mTOR,
along with p53, spares the available serine for glutathione synthesis by
stimulation of PKM2 protein synthesis, which links glycolysis to
anabolic pathways [319]. Moreover, mTOR suppresses autophagy and
mitophagy and, therefore, produces ROS. AMP-activated protein ki-
nase (AMPK), an mTOR inhibitor, plays a vital role in metabolic flux and
regulates GLUT4 expression, mitochondrial biogenesis and fatty acid
oxidation. Complex interaction between mTOR, AKT, and AMPK to
regulate GLUT4 translation has also been shown [320]. Activated AKT
phosphorylates and inhibits AS160 Rab GTPase activating protein in
the cytoplasm leading to increased translocation of the insulin-
responsive glucose transporter, GLUT4 to the membrane [321]. Also,
ADP and ATP play a critical role in the stability of AKT phosphorylation
at residues T308 and S473 and, therefore, act as on/off switches as
ATP binds to these phosphorylated sites and protects them against
phosphatases. Consequently, AMPK regulates AKT phosphorylation by
responding to the equilibrium of the adenylate pool [320,322]. On the
other hand, Kumar et al. [323], reported that FRic/ murine fat cells,
with ablated Rictor, showed impaired insulin-stimulated GLUT4
translocation to the plasma membrane and decreased glucose
transport.
Given the integral role that mTOR plays in oxygen and nutrient sensing,
it is notable that several miRNAs may directly or indirectly influence
mTOR activity. Increased expression of MTOR coexists with down-
regulation of several miRNAs in various types of cancer (Table 5 and
Figure 2). Examples include miR-99a/b, miR-100, and miR-199b in
cancers, including endometrial cancer, esophageal squamous cell
carcinoma, and bladder cancer [324e327]. miR-99 and miR-100
were also reported to be endogenous inhibitors of mTOR protein
abundance [328]. miR-7 was found to target MTOR directly and form a
negative feedback loop by also directly repressing EGFR and thus
results in pleiotropic inhibition of protein translation [329,330]. Chen
et al. and Lin and Shao et al. [331,332] reported a significant inhibition
of mTOR expression, at both RNA and protein levels, by miR-101. Also,
miR-373 and miR-520c were reported to reduce MTOR mRNA and
protein levels and increase MMP9, which consequently results in the
increased migration and invasion capability of cancer cells [333]. A
negative regulator of mTOR is TSC1/2 complex. miR-451 was found to
target TSC1 and stimulate the stemness phenotype of myeloma cells
through activation of the PI3K/AKT/mTOR pathway [334,335]. These
findings further highlight the role of mTOR, situated at the crossroads
of cancer-related signaling pathways. They show the interplayccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 107
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tical implications for cancer therapy.
5.5. Tumor protein p53 (TP53)
p53 is a transcription factor and tumor suppressor that plays critical
roles in controlling cell cycle progression through DNA damage
response and apoptosis, which has been shown to regulate both
glycolysis and OXPHOS [190]. In general, p53 inhibits glycolysis
transcriptionally by supressing GLUT1, GLUT3, and PGM expression.
Therefore, loss of p53 function in many cancers contributes to either
glycolysis or the pentose phosphate pathway (PPP) [155,336]. Mutated
p53 was shown to reduce oxygen consumption and mitochondrial
respiration. First, diminished p53 activity reduces OXPHOS by elimi-
nating its suppression of SCO2, a protein essential for COX assembly
and mitochondrial respiration [337]. Moreover, p53 may affect mtDNA
by regulating the expression of ribonucleotide reductase subunit
p53R2 and, ultimately, regulating mitochondrial oxidative respiration
[338]. P53R2 plays important roles in both the biogenesis of mito-
chondria and mtDNA maintenance [339]. Although p53 induces
oxidative stress by its pro-apoptotic function, it can also adversely
impact redox maintenance [340]. Anti-oxidant roles of p53 include
upregulation of GLS2 and subsequent increase in glutathione as well
as enhanced stability of NRF2, an important antioxidant transcription
factor, under oxidative stress [341,342]. Other p53 functions that
regulate metabolism include induced PTEN expression, which inhibits
the PI3K pathway and glycolysis, cooperation with the OCT1 tran-
scription factor to modulate the balance between glycolysis and
OXPHOS and reduced fatty acid oxidation in response to metabolic flux
[343e345].
The identification of several miRNAs that target p53 implies complex
regulation and may explain the development of malignancies in cells
with wild-type p53, where miRNA-mediated repression of TP53 and its
transactivational genes, such as CDKN1A, BBC3, DNM1L, and BAX, is
sufficient to cause tumourigenesis [346,347]. p53 both regulates, and
is regulated by, miRNAs. Many of these miRNAs were shown to directly
target TP53 in different systems (summarized in Table 5). It is
becoming clear that most of these miRNAs represent conservative
regulation of p53 activity, targeting multiple components of the p53
pathway. Also, the functional overlap between these miRNAs indicates
the potential for cumulative miRNA dysregulation influencing the p53
network during tumourigenesis. p53 suppresses glucose transporters
and glycolytic enzymes by enhancing TIGAR [348]. TIGAR is best
characterized by its negative regulation of fructose-2, 6-
bisphosphatase. Eventually, TIGAR directs glucose to PPP and en-
hances NADPH production [349]. miR-144 targets TIGAR and modu-
lates autophagy, apoptosis and metastasis in lung cancer cells [350].
In order to survive, cancer cells can also render p53 inactive by point
mutation or through degradation induced by the E3 ubiquitin ligase,
(MDM2) [351,352]. Aside from gene mutations, promoter (de)
methylation and proteolytic degradation, MDM2 is regulated by miR-
NAs. miRNAs such as miR-605 and miR-660 directly target MDM and
modulate MDM:p53 interaction, aiding rapid stabilization and accu-
mulation of p53. On the other hand, p53 trans-activates the expression
of the miR-605 host gene PRKG1 through binding to its promoter re-
gion, which results in a positive feedback loop and increased p53
activity [353,354]. Other miRNAs that suppress MDM2 include miR-
509-5p in HCC and cervical cancer, miR-29b in non-small cell lung
cancer (NSCLC), miR-143/145 in head and neck squamous cell car-
cinoma (HNSCC), miR-192, miR-215, miR-194, and miR-339-5p in
renal cell adenocarcinoma, breast cancer, and colorectal cancer
[355e358] (Figure 2).108 MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. TIn addition to the aforementioned functions of p53 in regulating cell
metabolism, miRNA biosynthesis also involves p53-signaling compo-
nents. p53 interacts with the Drosha complex and accelerates the
processing of targeted primary miRNA sequences to precursor miRNA
fragments [359]. Specific miRNAs are also transcriptionally regulated
by p53 [355,360,361] (Table 4). Most of these p53-responsive miRNAs
are involved in both positive and negative feedback loops. For instance,
members of the miR-34 family are induced through p53 binding to
their promoter in response to stress and, in turn, TP53 mRNA has been
validated as a direct target of miR-34 [362,363]. miR-605 and miR-
509-5p/MDM2/p53 are examples of positive feedback loops where
p53 induces miRNA synthesis and miR-509-5p and miR-605 target
MDM2 to increase p53 protein levels [353,355]. miR-17-5p/TP53INP1/
p53 is another regulatory feedback loop. miR-17-5p targets TP53INP1
mRNA transcript which encodes a p53-induced nuclear protein and
also is a direct target of p53; so, miR-17-5p functions as a mediator in
a regulatory loop in colon and cervical cancer [361]. Other miRNAs that
target tumor protein P53 inducible nuclear protein 1 (TP53INP1)
include miR-130b in hepatocarcinoma, miR-155 in pancreatic cells,
and miR-125b in endometrial carcinoma [364e366]. Therefore, both
regulation of the p53 network by miRNAs, and p53 induction of miRNA
levels, are tightly coordinated to enable response to stimuli.
These findings show that the p53 network is more complex than
previously envisioned and suggest that additional regulatory layers,
incorporating miRNAs, provide derepression of TP53 enabling it to
accumulate rapidly in response to cell stress. The aforementioned
functions establish a new driver of the Warburg effect and demonstrate
that p53 may act as a “brake” on glycolysis and neoplastic cell
proliferation.
5.6. Sirtuins
Sirtuins are a conserved family of NADþ-dependent deacetylases.
Advances in sirtuin biology have identified multiple targets for the
seven mammalian sirtuins (SIRT1-7) and, recently, their participation
in tumourigenesis and regulation of cancer cell metabolism [378].
SIRT1 is a nuclear protein that shuttles between the nucleus and
cytoplasm, especially when insulin signaling is inhibited [379]. SIRT1
modulates several cellular pathways by deacetylating a subset of
nuclear and cytosolic targets. AMPK and SIRT1 cooperate in the in-
duction of gluconeogenesis, glycolysis and lipid catabolism, mito-
chondrial biogenesis and respiration by phosphorylation and then
deacetylation of PPARgamma coactivator 1alpha (PGC1a) and FOXO
transcription factors [380e383]. A homeostatic and negative feedback
loop has been reported among SIRT1, p53, FOXO3A, and FOXO1.
During energy stress FOXO3A binds to p53 promoter, repressing SIRT1
expression, and in turn SIRT1 inhibits p53 activity by excessive
deacetylation and also through FOXO3A activation [384e386]. In
addition, SIRT1 is involved in the oxidative response, working together
with HIF-1, p53, and Myc [387].
SIRT6 is another member of the sirtuin nuclear histone deacetylase
(HDAC) family, which exerts both nuclear ADP-ribosyltransferase ac-
tivity and deacetyltransferase activity with roles in epigenetic regula-
tion of genomic stability, cellular metabolism, stress response, aging,
and cancer [388e391]. Yin and Gao et al. [392] showed that neuronal
SIRT6 overexpression significantly suppresses insulin-like factor 2
(IGF2) activity and other proteins such as AKT and mTOR at the
chromatin level. SIRT6 activation results in inhibition of HIF-1,
glycolysis, and respiration, as well as induction of homologous and
non-homologous DNA repair. The latter function of SIRT6 occurs
through ADP-ribosylation of poly(ADP-Ribose) polymerase 1 (PARP-1)
[393,394]. SIRT6 regulates HIF-1 and c-Myc expression, at thehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 4 e Summary of miRNAs regulated by the transcription factor p53.
miRNA Regulation Disease/cells References
Let-7a/b Downregulation Colorectal Cancer [367]
miR-17 Downregulation Colorectal Cancer [133]
miR-20a Downregulation Colorectal Cancer [133]
miR-29 Upregulation Colorectal Cancer [368]
miR-200c Upregulation Mammary Gland, Colorectal
Cancer
[369,370]
miR-183 Upregulation Mammary Gland [369]
miR-34a/b/c Upregulation Colorectal Cancer, Non-Small
Cell Lung Cancers, Ovary Clear
Cell Carcinoma, Osteosarcoma,
Pancreatic Cancer, Prostate
Cancer, Ovarian Carcinoma
[362,371e375]
miR-605 Upregulation Breast Cancer, Lung Carcinoma [353]
miR-145 Upregulation Breas Cancer, Colorectal
Cancer
[241]
miR-192 Upregulation Colorectal Cancer, Multiple
Myeloma, Ovary Clear Cell
Carcinoma, Osteosarcoma
[358,370,372,376]
miR-194 Upregulation Multiple Myeloma, Colorectal
Cancer
[358,376]
miR-215 Upregulation Colorectal Cancer, Multiple
Myeloma, Ovary Clear Cell
Carcinoma, Osteosarcoma
[358,370,372,376]
miR-141 Upregulation Colorectal Cancer [370]
miR-519d Upregulation Hepatocellular Carcinoma [286]
miR-107 Upregulation Colorectal Cancer [151,377]
miR-509 Upregulation Cervical Cancer, Hepatocellular
Carcinoma
[355]transcriptional level, through chromatin deacetylation and also regu-
lates HIF-1 stability through an unknown mechanism [395]. Mos-
toslavsky et al. [396] reported a novel role for SIRT6 in glucose
homeostasis in mice. Accordingly, subsequent studies confirmed its
vital role in direct and indirect regulation of glucose uptake and
metabolism. Nevertheless, SIRT6 was found to transcriptionally
regulate some c-Myc targets involved in ribosomal biogenesis and
glutamine utilization, rather than those involved in regulating cancer
cell glycolysis [397]. In contrast to SIRT6 that acts independently,
SIRT1 cooperates with c-Myc to suppress p53 activity and increase c-
Myc-induced LDHA expression [395]. SIRT7 is a nucleolar sirtuin
member that activates transcription by binding to RNA polymerase
[398,399]. Vakhrusheva et al. [400] reported a p53 hyperacetylation
state in SIR7 knockout mice, which results in increased apoptosis and
decreased resistance to oxidative stress.
The miRNA-mediated regulation of nuclear sirtuins, with an emphasis
on SIRT1 and SIRT6, has highlighted their roles in glycolysis. SIRT1 has
been the most extensively studied member in this context. miR-34a
was the first discovered SIRT1 targeting miRNA. miR-34 is a p53-
related miRNA that most importantly regulates cell cycle. miR-34
downregulates SIRT1 expression by directly binding to its 30UTR and
indirectly through targeting nicotinamide phosphoribosyltransferase
(NAMPT), the rate limiting enzyme in NADþ biosynthesis [401e403].
Xu et al. [404] reported SIRT1 targeting by miR-22, which modulates
the retinoblastoma signaling pathway. miR-204 targets SIRT1 in
osteocarcinoma cells and inhibits epithelialemesenchymal transition
(EMT) of the cancer cells [405]. Similarly, miR-200c has been reported
to form a negative feedback loop with SIRT1, attenuating epithelial to
mesenchymal transition (EMT) in breast cancer cells [406]. Likewise,
miR-181a and miR-9 regulate SIRT1 and impact insulin signaling,
glucose homeostasis and cell apoptosis [407e409]. miR-143, miR-93
and miR-217 lead to decreased glucose uptake, downregulatedMOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.commicrosomal glutathione S-transferase 1 and inhibited angiogenesis,
respectively, by targeting SIRT1 [410e412]. Several other miRNAs that
modulate SIRT1 expression and activation include miR-9, miR-34c,
miR-132, miR-135, miR-146, miR-181b, miR-195, miR-199, and
miR-499 [413e417] (Figure 2).
Post-transcriptional regulation of SIRT6 by miR-33a/b plays a vital role
in regulation of cholesterol and lipid metabolism via acetylation of its
targets [392,418e420]. Sharma et al. [421] reported a negative
feedback loop between SIRT6 and miR-766 in dermal fibroblasts.
SIRT7 expression is elevated in highly metabolic and proliferative cells
and was reported to be a target of miR-125a/b inducing G1 cell cycle
arrest [422].
SIRT2 is predominantly cytosolic but it also shuttles to the nucleus and
is mainly enriched in the brain [423]. SIRT2 was reported to deace-
tylate histone H3, p300, FOXO1, FOXO3A, adenomatous polyposis coli
(APC), cell division cycle 20 (CDC20), p65, PGM, phosphoenolpyruvate
carboxykinase 2 (PEPCK), and receptor-interacting protein 1 (RIP1)
and, therefore, regulates cell cycle, genome integrity, energy ho-
meostasis, gluconeogenesis, glycolysis, oxidative stress modulation,
cell growth, and death [424e430]. miR-339 was shown to target
SIRT2, increasing NF-KB and FOXO1 acetylation in neuroblastoma cells
[431]. Moreover, in silico analysis revealed a longevity associated SNP
of SIRT2 within the binding site of three miRNAs (called miRSNPs).
Therefore, miR-3170, miR-92a-1-5p and, more importantly, miR-615-
5p were predicted to target SIRT2 resulting in reduction in SIRT2
expression [432]. Li and Dai et al. [284] showed that SIRT2 is
downregulated in glioma. SIRT2 acts as a tumor suppressor and in-
hibits glioma growth by targeting miR-21 expression through deace-
tylating p65 and blocking p65 binding to the miR-21 promoter.
Regulation of miR-21 activity is particularly important as this miRNA
displays significant oncogenic activity [433].
Three mitochondrial sirtuins are SIRT3, SIRT4, and SIRT5. SIRT3 is the
major mitochondrial sirtuin, which promotes ATP production by
regulating TCA cycle enzymes such as acetyl COA synthetase, IDH2,
glutamate dehydrogenase 1 (GDH) and SDH during energy stress. GDH
upregulation leads to an induction in glutamine metabolism which
consequently produces more ATP and releases insulin [434e437]. It
also upregulates Mn superoxide dismutase (MnSOD), downregulates
ROS, HIF-1, and p53 and activates FOXO3A to modulate redox ho-
meostasis and maintain mitochondrial membrane potential [438e
442]. SIRT3-mediated regulation of OXPHOS components has been
shown. The targets include components of complex I, II, III and V such
as NDUFA11/S8, SDHA/B and ATP5A1/B1/F1 [438,443,444]. Alto-
gether, SIRT3 is capable of reversing the Warburg effect toward
mitochondrial predominance and ATP synthesis. SIRT4 is another
mitochondrial sirtuin which seems to function as a tumor suppressor
by downregulating GDH through ADP-ribosylation activity and conse-
quently suppressing glutamine utilization and the flow of amino acids
into the TCA cycle [434]. Nasrin et al. [445] showed that reduced SIRT4
results in increased fatty acid oxidation and mitochondrial metabolism.
They also demonstrated an increase in SIRT1 expression levels. miR-
193 mediated suppression of SIRT3 leads to impaired energy meta-
bolism and ATP synthesis in myocardium [446]. miR-23a was also
shown to target PGC1 and thereby indirectly modulate SIRT3 expres-
sion [447]. Moreover, upregulation of miR-28-5p, resulting from
oxidative stress, directly targets SIRT3 [448]. Liang et al. [449] re-
ported SNPs in the miR-105 and miR-532 binding sites in the SIRT3
30UTR that are associated with ovarian cancer treatment responses. In
addition, Slaby et al. [450] reported three miRNAs that are regulated by
natural agents called isothiocyanates in colorectal cancer (CRC) cells.
In silico analysis also revealed CRC-related SNPs within the 30UTR ofccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 109
Table 5 e Summary of miRNAs targeting metabolism-related oncogenes and tumor suppressors S indicates references in Supplementary file.
miRNAs Gene Disease References
Let-7 KRAS, MYC Breast Cancer, Colorectal Cancer, Lung Cancer, Glioma, Malignant Mesothelioma,
Oropharyngeal Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Gastric
Cancer, Prostate Cancer, Burkitt Lymphoma, Malignant Bronchial Epithelial Cell,
Pulmonary Hypertension
S [1e8], [199,205,224,234,236]
miR-1 KRAS, EGFR, PTEN Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma,
Cardiovascular Disease
S [9e11], [298]
miR-100 mTOR Esophageal Squamous Cell Carcinoma, Bladder Cancer, Endometrioid Endometrial
Carcinoma, Breast Cancer
S [12], [325e327]
miR-101 KRAS, MYC, AKT,
mTOR, TIGAR
Hepatocellular Carcinoma, Osteosarcoma, Clear Cell Renal Cell Carcinoma, Prostate
Cancer
S [13e15], [331,332]
miR-105 SIRT3 Ovarian Cancer [449]
miR-106a/b SIRT1, PTEN Pituitary Tumor, Breast Cancer S [16e18]
miR-107 EGFR Non-Small Cell Lung Cancer S [19]
miR-10b PTEN Breast Cancer S [20]
miR-122/a MYC, EGFR Hepatocellular Carcinoma, Inflammatory Bowel Disease S [21], [231]
miR-124a SIRT1 Neuropathic Pain S [22]
miR-125a/b SIRT1, SIRT7, TP53 Hepatocellular Carcinoma, Age-Related Cataract, Multiple Myeloma, Non-Small Cell
Lung Cancer, Colorectal Cancer, Neuroblastoma, Cataract
S [23e28], [422]
miR-126 KRAS, AKT Pancreatic Cancer, Squamous Tongue Cell Carcinoma, Glioma, Colorectal Cancer S [29,30], [204,263]
miR-1285 TP53 Neuroblastoma, Hepatoblastoma S [31]
miR-1294 MYC Esophageal Squamous Cell Carcinoma S [32]
miR-1297 PTEN Breast Cancer S [33]
miR-130a/b MYC, PTEN Osteocarcinoma, Bladder Carcinoma, Non-small Cell Lung Cancer S [34e36], [223]
miR-132 SIRT1 Glioma, Type2 Diabetes Mellitus, Gastric Cancer, Colitis S [37e40]
miR-133a/b EGFR, SIRT1 Pancreatic Cancer, Ovarian Cancer, Hepatocellular Carcinoma S [41,42]
miR-134 KRAS, EGFR Rena Cell Carcinoma, Glioblastoma, Non-Small Cell Lung Cancer, Colorectal Cancer S [43e45], [207]
miR-135a/a-1 MYC, EGFR Renal Cell Carcinoma, Prostate Cancer S [46,47]
miR-137 EGFR Glioblastoma Multiforme, Thyroid Cancer S [48,49]
miR-138 SIRT1 Diabetic Vascular Smooth Muscle Cells, Intervertebral Disc Degeneration, Pancreatic
Cancer, Osteocarcinoma
S [50e53]
miR-141 PTEN, AKT, TP53,
SIRT1
Esophageal Cancer, Osteosarcoma, Multiple Myeloma, Pluripotent Stem Cells, Glioma,
HB infection
S [25,54e57], [272]
miR-142 PTEN Cutaneous Squamous Cell Carcinoma S [58]
miR-143 KRAS, EGFR, AKT,
MDM2, SIRT1
Colorectal Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Head and Neck
Squamous Cell Carcinoma, Pancreatic Cancer
S [59e63], [266,357,410]
miR-144 PTEN, mTOR, TIGAR Pancreatic Neuroendocrine Tumor, Preeclampsia, Salivary Adenoid Carcinoma, Renal
Cell Carcinoma, Inflammation of Microglia, Lung Cancer
S [64e67], [350]
miR-145 MYC, MDM2, SIRT1 Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Ovarian Cancer,
Oral Squamous Cell Carcinomas, Glioblastoma, Head and Neck Squamous Cell
Carcinoma, Pancreatic Cancer
S [68e70], [266,357,410]
miR-146b AKT Osteosarcoma [272]
miR-148a/b PTEN, AKT, MYC Osteosarcoma, Renal Cell Carcinoma, Hepatocellular Carcinoma S [71,72], [2,229]
miR-149 AKT Hepatocellular Carcinoma, Neuroblastoma, Glioblastoma Multiforme S [73e75]
miR-150 TP53 Lung Cancer S [76]
miR-152 PTEN, SIRT7 Hepatic Insulin Resistance, Human Dental Pulp Stem Cells S [77,78]
miR-153 PTEN, AKT Prostate Cancer, Lung Cancer [275,276]
miR-155 KRAS, MYC, PTEN,
AKT, SIRT5, SIRT1
Gastric Carcinoma, hepatocellular Carcinoma, Waldenström Macroglobulinemia,
Leukemia, Colorectal Cancer, Neuropathic Pain
S [22,79e81], [220,301,450]
miR-15a/b, miR-16 TP53, mTOR, AKT,
SIRT4
Multiple Myeloma, Glioma, Ischemia, Dermal Fibroblasts S [25,82e85]
miR-17 MYC, TP53 Neuroblastoma, Cervical Cancer S [86], [361]
miR-18/a KRAS Human Squamous Carcinoma, Colorectal Cancer, Liver Cancer, Ovarian Cancer S [87,88]
miR-181a/b/d PTEN, KRAS, EGFR,
AKT, SIRT1
Colorectal Cancer, Osteosarcoma, Oral Squamous Cell Carcinoma, Glioma, Cutaneous
Squamous Cell Carcinoma, Acute Myeloid Leukemia, Glioblastoma Multiforme, Hepatic
Stellate Cells, Non-Alcoholic Fatty Liver Diseases
S [89e97]
miR-1827 MDM2 Colorectal Cancer S [98]
miR-183 mTOR Neuropathic Pain S [99]
miR-184 MYC Non-Small Cell Lung Cancer, Nasopharyngeal Carcinoma S [100,101]
miR-185 MYC, PTEN, AKT Colorectal Cancer, Breast Cancer, Hepatocellular Carcinoma, Idiopathic Pulmonary
Fibrosis, Non-Small Cell Lung Cancer
S [102e104], [228,297]
miR-192 MDM2 Colorectal Cancer, Multiple Myeloma [358,376]
miR-193a/b PTEN, KRAS, TSC1/2 Renal Cell Carcinoma, Colon Cancer, Breast Cancer, Pancreatic Ductal
Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Amyotrophic Lateral
Sclerosis
S [105e108], [202,208]
miR-194 AKT, MDM2 Gall Bladder Cancer, Multiple Myeloma S [109], [358,376]
miR-195 SIRT3 Myocardium [446]
miR-197 TP53 Non-Small Cell Lung Cancer S [110]
miR-199a/b SIRT1, mTOR Pluripotent Stem Cells, Hyperglycemia-Induced Pancreaticb-Cell Loss, Endometrioid
Endometrial Carcinoma
S [111,112], [325]
miR-19a/b PTEN, TP53 Bladder Cancer, Osteosarcoma, Myeloma, Liver Cancer, Breast Cancer S [113e116]
Review
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Table 5 e (continued )
miR-200a/c EGFR, TP53, KRAS,
PTEN, SIRT1, MYC,
AKT
Bladder Cancer, Breast Cancer, Multiple Myeloma, Nasopharyngeal Carcinoma,
Colorectal Cancer, Hepatic Stellate Cell, Pluripotent Stem Cell, Lung Adenocarcinoma,
Renal Cell Carcinoma, Ovarian Cancer, Esophageal Cancers
S [25,117e126], [271,334]
miR-203 MYC Cutaneous Squamous Cell Carcinoma S [127]
miR-204 SIRT1 Osteosarcoma, Spermatogonial Stem Cell, Hepatocellular Carcinoma S [128,129], [405]
miR-205 PTEN Ovarian Cancer S [130]
miR-206 KRAS, EGFR Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Oral Squamous Cell Carcinoma,
Head and Neck Squamous Cell Carcinoma
S [10,131e133]
miR-20a/b PTEN, AKT, SIRT7 Coronary Artery Disease, Diabetic Retinopathy, Diabetic Nephropathy S [134e136]
miR-21 KRAS, MYC, PTEN Lung Cancer, Breast Cancer, Diabetic Kidney Disease, Colorectal Cancer,
Hepatocellular Carcinoma, Leukemia, Vestibular Schwannomas, Glioblastoma, Bladder
Cancer, Radio-resistance Lung Cancer
S [5,137e142], [296,305]
miR-210 MYC Colorectal Cancer, Glioblastoma, Cervical Cancer, Breast Cancer S [143]
miR-212 SIRT1 Prostate Cancer S [144]
miR-214 KRAS, PTEN, TP53 Non-small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Ovarian Cancer Stem
Cells
S [145e148], [291]
miR-215 MDM2 Colorectal Cancer, Multiple Myeloma [358,376]
miR-216a/b PTEN, KRAS Acute Pancreatitis, Kidney Disorders, Ovarian Cancer, Nasopharyngeal Carcinoma S [149e151], [289]
miR-217 KRAS, PTEN, SIRT1 Pancreatic Ductal Adenocarcinoma, Lung Cancer, Kidney Disorders, Podocyte Injury,
Aging
S [152e154], [289,411]
miR-218 EGFR, mTOR Non-Small Cell Lung Cancer, Prostate Cancer S [155,156]
miR-22 MYC, PTEN, SIRT1 Leukemia, Clear Cell Renal Cell Carcinoma, Glioblastoma, Ischemia-Reperfusion Injury S [157e161], [225]
miR-221 PTEN Radiosensitive Cancer Cells, Glioblastoma S [162], [293]
miR-222 PTEN, TP53 Radiosensitive Cancer Cells, Oral Squamous Cell Carcinoma S [162], [346]
miR-224 KRAS, mTOR Colorectal Cancer, Gastric Cancer S [163,164]
miR-23a/b EGFR, SIRT5, SIRT1 Coronary Artery Disease, Colorectal Cancer, Diabetic Retinopathy S [165,166], [450]
miR-24 MYC, TP53 Leukemia, Embryonic Stem Cells, Hepatocellular Carcinoma S [167,168], [227]
miR-25 PTEN, TP53 Diabetic Nephropathy, Multiple Myeloma, Non-Small Cell Lung Cancer, Colorectal
Cancer
S [25,169,170]
miR-26a PTEN Glioblastoma [282]
miR-27a/b KRAS, TP53, EGFR,
SIRT5
Esophageal Squamous Cells Carcinoma, Colorectal Cancer, Renal Cell Carcinoma,
Non-Small Cell Lung Cancer
S [47,171e173], [450]
miR-28 SIRT3 Primary human tenocytes [448]
miR-29a/b/c PTEN, AKT, MDM2 Colorectal Cancer, Gastric Cancer, Prostate Cancer, Breast Cancer, Non-Small Cell
Lung Cancer
S [174e177], [265,288,356]
miR-300 TP53 Lung Cancer, Colorectal Cancer S [178,179]
miR-301a PTEN Pancreatic Cancer, Malignant Melanoma S [180,181]
miR-302a AKT Prostate Cancer [264]
miR-30b/c/d KRAS, TP53 Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma,
Cardiac Disease
S [170,182e184], [347]
miR-31 TP53 Breast Cancer S [185]
miR-3151 TP53 Malignant Melanoma S [186]
miR-32 PTEN Hepatocellular Carcinoma [287]
miR-320a MYC Hepatocellular Carcinoma S [187]
miR-33 TP53 Hematopoietic Stem Cells S [188]
miR-337 PTEN Endometrial Carcinoma S [189]
miR-338 mTOR Colon Cancer S [190]
miR-339 MDM2, SIRT2 Breast Cancer, Neuroblastoma S [191], [431]
miR-33a/b/c SIRT6, MYC Liver Cancer, Osteosarcoma [219,418]
miR-340 MDM2 Prostate Cancer S [192]
miR-34a MYC, EGFR, AKT,
SIRT6, SIRT1
Hepatocellular Carcinoma, Prostate Cancer, Renal Cell Carcinoma, Non-Small Cell
Lung Cancer, Glioma, Colorectal Cancer, Non-Alcoholic Fatty Liver Diseases,
Pancreatic Cancer
S [193e197], [222,240,268,410]
miR-363 MYC Prostate Cancer, Hepatocellular Carcinoma S [198], [2]
miR-365a KRAS Cutaneous Squamous Cell Carcinoma S [106]
miR-3666 SIRT7 Breast Cancer S [199]
miR-367 MDM2 Hepatocellular Carcinoma S [200]
miR-370 EGFR, PTEN Gastric Cancer, Colorectal Cancer, Gastric Cancer S [45,201,202]
miR-373 mTOR, SIRT1 Fibrosarcoma [333]
miR-374/a MDM2, PTEN Bladder Cancer, Breast Cancer S [203,204]
miR-377 SIRT1 Obesity S [205]
miR-378 AKT Breast Cancer S [206]
miR-380 TP53 Neuroblastoma S [207]
miR-384 KRAS Colorectal Cancer S [208]
miR-409 AKT Breast Cancer S [209]
miR-421 SIRT3 Non-Alcoholic Fatty Liver Disease S [210]
miR-429 MYC Gastric Cancer, Breast Cancer S [119,211]
miR-449a/c MYC Glioblastoma, Gastric Carcinoma, Osteosarcoma, Prostate Cancer S [212e214]
miR-451 MYC, AKT Docetaxel-Resistant Lung Adenocarcinoma, Dilated Cardiomyopathy, Bladder Cancer,
Non-Small Cell Lung Cancer, Glioblastoma
S [215e220]
(continued on next page)
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miR-451 TSC1/2 Multiple Myeloma, Hypertrophic Cardiomyopathy S [221], [335]
miR-453 TP53 Lung Cancer S [222]
miR-4534 PTEN Prostate Cancer S [223]
miR-454 PTEN Non-Small Cell Lung Cancer S [224]
miR-4689 KRAS, AKT Colorectal Cancer, [203]
miR-486 PTEN, MDM2, SIRT1 Cardiac Myocytes, Lung Cancer, Erythroleukemia S [225,226], [283]
miR-491 TP53 Pancreatic Cancer S [227]
miR-492 PTEN Hepatic Cancer S [228]
miR-494 MYC, PTEN, SIRT1 Epithelial Ovarian Cancer, Cardiac Disease, Myeloid-Derived Suppressor Cells, Cervical
Cancer, Gastric Carcinoma, Pancreatic Cancer
S [229e233], [294,304]
miR-495 AKT, mTOR Prostate Cancer S [234]
miR-496 mTOR Aging S [235]
miR-5003 MDM2 Breast Cancer S [236]
miR-502a EGFR Colorectal Cancer S [237]
miR-504 TP53 Non-Small Cell Lung Cancer, Colorectal Cancer, Multiple Myeloma, Abdominal Aortic
Aneurysm
S [170,238], [360]
miR-509 EGFR, MDM2 Tongue Squamous Cell Carcinoma, Cervical Cancer, Hepatocellular Carcinoma,
Prostate Cancer
S [239,240], [355]
miR-511 AKT Prostate Cancer S [241]
miR-519d PTENAKT Hepatocellular Carcinoma [286]
miR-520 b/c/e EGFR, mTOR, SIRT1 Gastric Cancer, Fibrosarcoma S [242], [333]
miR-532 KRAS, SIRT3 Lung Adenocarcinoma, Ovarian Cancer S [243], [449]
miR-543 SIRT1 Hypertension, Gastric Cancer S [244,245]
miR-545 EGFR Colorectal Cancer S [246]
miR-548i AKT Non-Small Cell Lung Cancer S [247]
miR-561 MYC Gastric Cancer S [248]
miR-577 PTEN Glioblastoma [283]
miR-579 MDM2 Melanoma S [249]
miR-600 TP53 Colorectal Cancer S [250]
miR-601 SIRT1 Pancreatic Cancer S [251]
miR-606 MDM2 Breast Cancer, Lung Cancer, Colorectal Cancer [353]
miR-610 MDM2 Glioma S [252]
miR-613 KRAS Ovarian Cancer S [253]
miR-615 AKT Pancreatic Ductal Adenocarcinoma S [254]
miR-622 KRAS Lung Cancer, Colorectal Cancer S [255,256]
miR-637 AKT Glioma [267]
miR-638 AKT Lung Cancer S [257]
miR-641 MDM2 Lung Cancer S [258]
miR-650 AKT Rheumatoid Arthritis S [259]
miR-660 MDM2 Lung Cancer [354]
miR-7 EGFR, mTOR Ovarian Cancer, Glioblastoma, Lung Cancer, Breast Cancer, Hepatocellular Carcinoma,
Gastric Cancer
S [260,261], [277e279,329,330]
miR-718 PTEN Kaposi’s Sarcoma, Inflammation S [262], [292]
miR-744 MYC Hepatocellular Carcinoma [221]
miR-758 mTOR, MDM2 Hepatocellular Carcinoma S [263]
miR-766 MDM2, SIRT6 Breast Cancer, Dermal Fibroblast S [264], [421]
miR-768 KRAS Lung Cancer S [265]
miR-875 EGFR Prostate Cancer S [266]
miR-9/a SIRT1PTEN Hepatic Stellate Cells, Non-Alcoholic Fatty Liver Disease, Acute Myeloid Leukemia,
Colorectal Cancer, Nasopharyngeal Carcinoma, Non-Small Cell Lung Cancer
S [267e272]
miR-92 TP53 Multiple Myeloma, Pluripotent Stem Cells S [25,55]
miR-923 AKT Lung Cancer S [257]
miR-93 MYC, PTEN, SIRT1 Colon Cancer, Ovarian Cancer, Myocardial Ischemia/Reperfusion(I/R) Injury, Breast
Cancer, Aging
S [18,273,274], [290,412]
miR-95 PTEN Radioresistance Lung Cancer S [138]
miR-96 KRAS, mTOR Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Colorectal Cancer, Myocardial
Hypertrophy
S [184,275e277], [206]
miR-98 MYC, TP53 Breast Cancer, Lung Cancer S [5,222]
miR-99a/b mTOR Breast Cancer, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrioid
Endometrial Carcinoma
[324,325,327]
Reviewgenes, including SIRT5, may influence binding of these isothiocyanate-
regulated miRNAs.
Collectively, SIRTs play important roles in a wide range of metabolic
pathways and interact with many transcriptional regulators. miRNAs
targeting SIRTs (summarized in Table 5) may modulate SIRT-related
signaling transduction and downstream effectors, providing insight
into novel therapeutic strategies.112 MOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. T6. TOWARDS FUTURE APPLICATIONS FOR DISRUPTING
CANCER CELL GLYCOLYSIS
Metabolomics provides a new exciting platform to explore potential
anti-cancer drugs. A universally observed phenotype of malignant
cells is their propensity to import glucose and secrete lactate, even
in the presence of oxygen. The characterization of aerobic glycolysishis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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has led to dramatic advances in tumor imaging. Positron emission
tomography (PET) scans, widely used for cancer diagnosis, exploit
the ability of cancer cells to sequester excessive glucose from the
blood stream. Ever since aerobic glycolysis was found to be a
characteristic of tumor cells and was accepted as a hallmark of
cancer, it has been proposed that suppressing aerobic glycolysis
would be a promising strategy to treat cancer. As a consequence,
several studies have reported the use of glycolytic enzyme inhibitors.
For instance, lonidamine as a HK2 inhibitor, PEP analogues as PKM
inhibitors, as well as FX-11 and panepoxydone as LDHA inhibitors,
have been considered potential therapeutic agents (reviewed in
[451,452]). However, as glycolysis is also a vital metabolic pathway
in normal cells, inhibition of aerobic glycolysis remains challenging
when identifying potential cancer-specific targets. Although a
definitive explanation for Warburg’s observations is overdue, the
control of this process by oncogenes and tumor suppressors,
coupled with epigenetic factors including microRNAs, provides
additional insight. So far, ample evidence supports associations
between the metabolic shift in cancer cells and oncogene activation
or inactivation of tumor suppressors. The elusive nature of metabolic
rewiring and branching in cancer cells, along with influences upon
other signaling pathways, raise concerns as to whether targeting a
single component of this complex circuit will be sufficient to erad-
icate cancer cells with minimal side effects. Despite several reports
of the involvement of miRNA-mediated gene regulation, there is still
much to learn about how miRNAs contribute to the Warburg effect.
Development of new miRNA-mediated strategies, that target meta-
bolic pathways rather than single components, have the potential to
enhance future cancer treatment. Systems biology approaches that
iteratively couple massively parallel gene expression analytical
technologies with high throughput functional screens, may identify
additional miRNAs or miRNA-targets with promise for cancer diag-
nosis, prognosis and drug development. Polymorphisms in the
miRNA binding sites of oncogenes are known to influence cancer
predisposition and therapeutic response, which may further inform
target selection [198,453]. Conversely, acquired somatic mutations
in miRNA-binding sites may also lead to the reduced efficacy of
miRNA-based therapies. Similarly, the demands of other tissues,
such as the highly glucose-dependent nature of brain and retina, will
necessitate tissue-specific delivery of anti-glycolysis miRNAs in a
therapeutic context where administration already presents chal-
lenges. Regardless, multi-faceted solutions are required to provide
hope for cancer patients who currently have limited options.
7. CONCLUSION
Aerobic glycolysis, a hallmark of cancer, is the consequence of specific
driver mutations and re-equilibrated homeostasis in tumor cells. While
cellular responses to the environment continue to involve the existing
signaling pathways, longer adaptive responses invoke post-
transcriptional and epigenetic control of gene expression. By regu-
lating multiple cellular pathways and multiple components of individual
pathways, microRNAs fine-tune expression to ensure high level buff-
ering of adaptive responses. Thorough understanding of these regu-
latory processes should provide the capacity to suppress metabolism
and inhibit cancer cell survival under stress. With the advent of RNA-
based therapies and the development of drugs that modulate the
activity of microRNA targets, or even microRNAs themselves, this re-
view has highlighted metabolic processes that may be disrupted by
novel therapeutic interventionsMOLECULAR METABOLISM 23 (2019) 98e126  2019 The Authors. Published by Elsevier GmbH. This is an open a
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ABBREVIATIONS
2HG 2-hydroxyglutarate
AGO argonaute
ALDO aldolase
AMPK AMP-activated protein kinase
APC adenomatous polyposis coli
C/EBPb CCAAT-enhancer-binding protein b
CDC20 cell division cycle 20
COX cytochrome c oxidase complex
CUL2 cullin 2
DNMT1 DNA (cytosine-5)-methyltransferase 1
EMT epithelial to mesenchymal transition
ENO1 enolase 1
EphA1 erythropoietin-producing hepatoma receptor A1
ERK extracellular-signal-regulated kinase
EZH2 enhancer of zeste homolog 2
FIH-1 factor inhibiting HIF-1
FOXO forkhead box O
GAPDH glyceraldehyde-3- phosphate dehydrogenase
GDH glutamate dehydrogenase 1
GLS glutaminase
GLS hypoxia-inducible factor-1
GLUTS: glucose transporters
GPD1L: glycerol-3-phosphate dehydrogenase 1 like
HDAC histone deacetylase
Her2/Neu human epidermal growth factor receptor 2
HK2 hexokinase 2
HNF3b hepatocyte nuclear factor 3-beta
HRE hypoxia response element
IDH isocitrate dehydrogenase
IGF2 insulin-like factor 2
ISCU iron-sulfur cluster scaffold
KLF15 Kruppel-like factor 15
LDHA lactate dehydrogenase A
MAGI2 membrane-associated guanylate kinase inverted 2
MAX MYC associated factor X
MCT monocarboxylate transporters
MDH malate dehydrogenase
miRNA microRNA
mitomiRs mitochondria-related microRNAsccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 113
ReviewMMP-2 metalloproteinase-2
MnSOD Mn Superoxide Dismutase
mTOR mechanistic target of rapamycin
NOX NADPH oxidase
OXPHOS oxidative phosphorylation
PARP-1 poly(ADP-ribose) polymerase 1
PDH pyruvate dehydrogenase
PDK1 pyruvate dehydrogenase kinase
PEPCK phosphoenolpyruvate carboxykinase 2
PET positron emission tomography
PFK1 6-phosphofructo-1-kinase
PGC1a PPARgamma coactivator 1alpha
PGK1 phosphoglycerate kinase 1
PGM phosphoglycerate mutase
PHD prolyl-4-hydroxylase
PKM1/2 pyruvate kinase isozymes M1/M2
PPP2R1B protein phosphatase 2 scaffold subunit Abeta
pre-miRNA precursor microRNA
pri-miRNA primary microRNA
PTEN phosphatase and tensin homolog
RIP1 receptor-interacting protein 1
RISC RNA-induced silencing complex
ROS reactive oxygen species
SCO2/1 synthesis of cytochrome c oxidase 2/1
SDH succinate dehydrogenase
SIRT sirtuin
STAT3 signal transducer and activator of transcription 3
TCA tricarboxylic acid
TGF-b: transforming growth factor beta 1
TIGAR TP53-induced glycolysis and apoptosis regulator
TLK transketolase
TP53INP1 tumor protein P53 inducible nuclear protein 1
TPI triose-phosphate isomerase
TSC tuberous sclerosis proteins
USP28 ubiquitin specific peptidase 28
VEGFA vascular endothelial growth factor A
VHL: Von Hippel-Lindau
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at https://doi.org/10.1016/j.
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